HORMONET: Phase II Study of Hormone Therapy with Tamoxifen in Patients with well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
This is a single-arm, single-stage clinical study of tamoxifen for patients with well-differentiated neuroendocrine tumors and radiological progression with positive (> 1%) HR (estrogen and/or progesterone) expression by immunohistochemistry (IHC).
Primary: To evaluate the efficacy of tamoxifen in patients with NETs that are well-differentiated, express HRs (estrogen and/or progesterone receptor), and are progressing. Secondary: (1) to evaluate progression-free survival; (2) to evaluate biochemical response; (3) objective response rate; (4) disease control rate according to HR expression intensity and primary site; (5) toxicities.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.